var data={"title":"Betamethasone (systemic): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Betamethasone (systemic): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/718330?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=betamethasone-systemic-drug-information\" class=\"drug drug_general\">see &quot;Betamethasone (systemic): Drug information&quot;</a> and <a href=\"topic.htm?path=betamethasone-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Betamethasone (systemic): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780847\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Celestone Soluspan;</li>\n      <li>Pod-Care 100C;</li>\n      <li>ReadySharp Betamethasone</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780848\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Betaject;</li>\n      <li>Celestone Soluspan</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24168309\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Corticosteroid, Systemic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24168315\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=betamethasone-systemic-drug-information\" class=\"drug drug_general\">see &quot;Betamethasone (systemic): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dosages expressed as combined amount of betamethasone sodium phosphate and betamethasone acetate; 1 mg is equivalent to betamethasone sodium phosphate 0.5 mg and betamethasone acetate 0.5 mg. Dosage should be based on severity of disease and patient response; use lowest effective dose for shortest period of time to avoid HPA axis suppression </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, treatment of inflammatory and allergic conditions:</b> Infants, Children, and Adolescents: IM: Initial: 0.02 to 0.3 mg/kg/day (0.6 to 9 mg/m<sup>2</sup>/day) in 3 or 4 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Infantile hemangioma, severe:</b> Limited data available: Infants and Children: Intralesional: Dosage dependent upon size of lesion: Commonly reported: 6 mg administered as a 6 mg/mL (in combination with triamcinolone injection) divided into multiple injections along the lesion perimeter; reported range: 1.5 to 18 mg/dose; doses usually administered every 8 to 14 weeks; reported range: 6 to 25 weeks (Buckmiller, 2008; Chowdri, 1994; Kushner, 1985; Praseyono, 2011). Dosing based on small trials and case-series, mostly reported in infants and children &le;4 years of age. The largest experience (n=70, age range: 2 months to 12 years) prospectively used a betamethasone/triamcinolone combination injection (1.5 to 18 mg betamethasone acetate) and showed that 89.23% of lesions with an initial volume &lt;20 cc<sup>3</sup> regressed by more than 50%, but only 22.2% of lesions with an initial volume &gt;20 cc<sup>3</sup> displayed a good or excellent response (Chowdri, 1994). Another trial (n=25, age range: 7 weeks to 2 years) used lower doses of 3 to 12 mg (in combination with triamcinolone); 16 patients experienced a marked response (Kushner, 1985). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note:</b> Dosages expressed as combined amount of betamethasone sodium phosphate and betamethasone acetate; 1 mg is equivalent to betamethasone sodium phosphate 0.5 mg and betamethasone acetate 0.5 mg. Base dosage on severity of disease and patient response </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing:</b> IM: Initial: 0.25 to 9 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Antenatal fetal maturation:</b> IM: In women with preterm premature rupture of membranes (membrane rupture between 24 0/7 weeks and 34 0/7 weeks of gestation), a single course of corticosteroids is recommended if there is a risk of preterm delivery (ACOG, 2013). Although the optimal corticosteroid and dose have not been determined, betamethasone 12 mg every 24 hours for a total of 2 doses has been used in most studies (Brownfoot, 2013). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bursitis (other than of the foot), tenosynovitis, peritendinitis:</b> Intrabursal: 3 to 6 mg (0.5 to1 mL) for 1 dose; several injections may be required for acute exacerbations or chronic conditions; reduced doses may be warranted for repeat injections</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dermatologic:</b> Intralesional: 1.2 mg/cm<sup>2</sup> (0.2 mL/cm<sup>2</sup>) for 1 dose (maximum: 6 mg [1 mL] weekly)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Foot disorders:</b> Intra-articular: 1.5 mg to 6 mg (0.25 to1 mL) per dose at 3- to 7-day intervals. Dose is based upon condition:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Bursitis: 1.5 mg to 3 mg (0.25 to 0.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Tenosynovitis: 3 mg (0.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Acute gouty arthritis: 3 mg to 6 mg (0.5 to1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Multiple sclerosis:</b> IM: 30 mg daily for 1 week, followed by 12 mg every other day for 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rheumatoid and osteoarthritis:</b> Intra-articular: 3 mg to 12 mg (0.5 to 2 mL) for 1 dose. Dose is based upon the joint size:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Very large (eg, hip): 6 to 12 mg (1 to 2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Large (eg, knee, ankle, shoulder): 6 mg (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Medium (eg, elbow, wrist): 3 to 6 mg (0.5 to 1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Small (eg, inter- or metacarpophalangeal, sternoclavicular): 1.5 mg to 3 mg (0.25 to 0.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780904\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pod-Care 100C: Betamethasone sodium phosphate 3 mg and betamethasone acetate 3 mg per 1 mL [contains benzalkonium chloride, disodium edta]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ReadySharp Betamethasone: Betamethasone sodium phosphate 3 mg and betamethasone acetate 3 mg per 1 mL [contains benzalkonium chloride, disodium edta]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Celestone Soluspan: Betamethasone sodium phosphate 3 mg and betamethasone acetate 3 mg per 1 mL (5 mL) [contains benzalkonium chloride, edetate disodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: Betamethasone sodium phosphate 3 mg and betamethasone acetate 3 mg per 1 mL (5 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780850\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24168316\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> May be coadministered with a local anesthetic.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: Do <b>not</b> give injectable suspension IV </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intrabursal: Tendinitis, tenosynovitis: Inject into affected tendon sheaths (not directly into tendons)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intralesional: Using a 25-gauge tuberculin syringe with <sup>1</sup>/<sub>2</sub>-inch needle inject a uniform depot; for infantile hemangioma, 26- and 27-gauge needles have been used for administration. Should be injected directly into the lesion area. Do <b>not</b> inject subcutaneously.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24171540\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 25&deg;C (77&deg;F); excursions are permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F). Protect from light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24168310\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: Anti-inflammatory or immunosuppressant agent in the treatment of a variety of diseases when oral therapy not feasible including those of allergic, hematologic, dermatologic, endocrine, gastrointestinal, ophthalmic, neoplastic, rheumatic, autoimmune, nervous system, renal, and respiratory origin (FDA approved in pediatric patients [age not specified] and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intra-articular or soft tissue administration: Adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis (FDA approved in pediatric patients [age not specified] and adults) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intralesional: Treatment of alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum (FDA approved in pediatric patients [age not specified] and adults); has also been used for treatment of infantile hemangioma.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780920\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cardiac failure, edema, hypertension, hypotension</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Dizziness, headache, increased intracranial pressure, insomnia, myasthenia, nervousness, pseudotumor cerebri, seizure, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Atrophic striae, diaphoresis, ecchymoses, facial erythema, fragile skin, hyperpigmentation, hypopigmentation, perioral dermatitis (oral)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Amenorrhea, Cushing's syndrome, diabetes mellitus, fluid retention growth suppression, hirsutism, HPA-axis suppression, hyperglycemia, hypokalemia, menstrual disease, protein catabolism, sodium retention</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal distention, dyspepsia, hiccups, increased appetite, pancreatitis, peptic ulcer, ulcerative esophagitis </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Petechia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Anaphylactoid reaction, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infection: Secondary infection, sterile abscess</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Injection site reaction (intra-articular use)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Amyotrophy, arthralgia, bone fracture, myopathy, osteonecrosis (femoral and humeral heads), osteoporosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Cataract, glaucoma, increased intraocular pressure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Wound healing impairment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780863\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to any component of the formulation; IM administration contraindicated in immune thrombocytopenia (formerly known as idiopathic thrombocytopenic purpura).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Herpes simplex of the eye; systemic fungal infections; vaccinia; cerebral malaria; use in areas with local infection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for glucocorticoids is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780864\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Patients receiving &gt;20 mg per day of prednisone (or equivalent) may be most susceptible. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do <b>not</b> provide the systemic steroid needed to treat patients having trauma, surgery, or infections. In stressful situations, HPA axis-suppressed patients should receive adequate supplementation with natural glucocorticoids (hydrocortisone or cortisone) rather than betamethasone (due to lack of mineralocorticoid activity).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid reactions: Rare cases of anaphylactoid reactions have been observed in patients receiving corticosteroids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunosuppression: Prolonged use of corticosteroids may increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate infections, or limit response to killed or inactivated vaccines. Special pathogens (<i>Amoeba</i>, <i>Candida</i>, <i>Cryptococcus</i>, <i>Mycobacterium</i>, <i>Nocardia</i>, <i>Pneumocystis</i>, <i>Strongyloides</i>, or <i>Toxoplasma</i>) may be activated or an infection exacerbation may occur (may be fatal). Amebiasis or <i>Strongyloides </i>infections should be particularly ruled out. Exposure to chickenpox or measles should be avoided; corticosteroids should not be used to treat ocular herpes simplex. Corticosteroids should not be used for cerebral malaria, fungal infections, or viral hepatitis. Close observation is required in patients with latent tuberculosis and/or TB reactivity; restrict use in active TB (only fulminating or disseminated TB in conjunction with antituberculosis treatment). Amebiasis should be ruled out in any patient with recent travel to tropic climates or unexplained diarrhea prior to initiation of corticosteroids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Kaposi sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi sarcoma (case reports); if noted, discontinuation of therapy should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myopathy: Acute myopathy has been reported with high-dose corticosteroids, usually in patients with neuromuscular transmission disorders; may involve ocular and/or respiratory muscles; monitor creatine kinase; recovery may be delayed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychiatric disturbances: Corticosteroid use may cause psychiatric disturbances, including depression, euphoria, insomnia, mood swings, and personality changes. Preexisting psychiatric conditions may be exacerbated by corticosteroid use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with HF and/or hypertension; use has been associated with electrolyte disturbances, fluid retention, and hypertension. Dietary modifications may be necessary. Use with caution in patients with a recent history of myocardial infarction (MI); left ventricular free wall rupture has been reported after the use of corticosteroids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus; may alter glucose production/regulation leading to hyperglycemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal disease: Use with caution in patients with GI diseases (diverticulitis,fresh intestinal anastomoses, peptic ulcer, ulcerative colitis) due to perforation risk. Avoid ethanol may enhance gastric mucosal irritation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Head injury: Increased mortality was observed in patients receiving high-dose IV methylprednisolone; high-dose corticosteroids should not be used for the management of head injury.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment, including cirrhosis; long-term use has been associated with fluid retention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; exacerbation of symptoms has occurred especially during initial treatment with corticosteroids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use. Not recommended for the treatment of optic neuritis; may increase frequency of new episodes. Consider routine eye exams in chronic users.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Osteoporosis: Use with caution in patients with osteoporosis; high doses and/or long-term use of corticosteroids have been associated with increased bone loss and osteoporotic fractures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; fluid retention may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroidism and decreases in hypothyroidism.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Because of the risk of adverse effects, systemic corticosteroids should be used cautiously in the elderly in the smallest possible effective dose for the shortest duration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: May affect growth velocity; growth should be routinely monitored in pediatric patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: For intramuscular, intra-articular or intralesional use only, do not administer intravenously or epidurally (see Epidural injection).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation of therapy: Withdraw therapy with gradual tapering of dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Epidural injection: Corticosteroids are not approved for epidural injection. Serious neurologic events (eg, spinal cord infarction, paraplegia, quadriplegia, cortical blindness, stroke), some resulting in death, have been reported with epidural injection of corticosteroids, with and without use of fluoroscopy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intra-articular injection: May produce systemic as well as local effects. Appropriate examination of any joint fluid present is necessary to exclude a septic process. Avoid injection into an infected site. Do not inject into unstable joints. Intra-articular injection may result in damage to joint tissues.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25820007\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Adrenal suppression with failure to thrive has been reported in infants after receiving intralesional corticosteroid injections for treatment of hemangioma (Goyal, 2004). May cause osteoporosis (at any age) or inhibition of bone growth in pediatric patients. Use with caution in patients with osteoporosis. In a population-based study of children, risk of fracture was shown to be increased with &gt;4 courses of corticosteroids; underlying clinical condition may also impact bone health and osteoporotic effect of corticosteroids (Leonard, 2007). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780922\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780921\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=95148&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B: Corticosteroids (Systemic) may enhance the hypokalemic effect of Amphotericin B. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Androgens: Corticosteroids (Systemic) may enhance the fluid-retaining effect of Androgens. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of Corticosteroids (Systemic). Management: No dose adjustment is needed for single 40 mg aprepitant doses. For other regimens, reduce oral dexamethasone or methylprednisolone doses by 50%, and IV methylprednisolone doses by 25%. Antiemetic regimens containing dexamethasone reflect this adjustment.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Axicabtagene Ciloleucel: Corticosteroids (Systemic) may diminish the therapeutic effect of Axicabtagene Ciloleucel.  Management: Avoid use of corticosteroids as premedication before axicabtagene ciloleucel. Corticosteroids may, however, be required for treatment of cytokine release syndrome or neurologic toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcitriol (Systemic): Corticosteroids (Systemic) may diminish the therapeutic effect of Calcitriol (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Corticosteroids (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Corticosteroids (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desirudin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Desirudin. More specifically, corticosteroids may increase hemorrhagic risk during desirudin treatment.  Management: Discontinue treatment with systemic corticosteroids prior to desirudin initiation.  If concomitant use cannot be avoided, monitor patients receiving these combinations closely for clinical and laboratory evidence of excessive anticoagulation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Corticosteroids (Systemic) may enhance the hyponatremic effect of Desmopressin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DilTIAZem: May increase the serum concentration of Corticosteroids (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May increase the serum concentration of Corticosteroids (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of Corticosteroids (Systemic). The active metabolite aprepitant is likely responsible for this effect.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indacaterol: May enhance the hypokalemic effect of Corticosteroids (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indium 111 Capromab Pendetide: Corticosteroids (Systemic) may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isoniazid: Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: Corticosteroids (Systemic) may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mifamurtide: Corticosteroids (Systemic) may diminish the therapeutic effect of Mifamurtide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May diminish the therapeutic effect of Corticosteroids (Systemic). MiFEPRIStone may increase the serum concentration of Corticosteroids (Systemic). Management: Avoid mifepristone in patients who require long-term corticosteroid treatment of serious illnesses or conditions (e.g., for immunosuppression following transplantation). Corticosteroid effects may be reduced by mifepristone treatment.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of Corticosteroids (Systemic).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents (Nondepolarizing): May enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nicorandil. Gastrointestinal perforation has been reported in association with this combination. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (Nonselective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Quinolones. Specifically, the risk of tendonitis and tendon rupture may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sargramostim: Corticosteroids (Systemic) may enhance the therapeutic effect of Sargramostim. Specifically, corticosteroids may enhance the myeloproliferative effects of sargramostim. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Corticosteroids (Systemic) may decrease the serum concentration of Tacrolimus (Systemic). Conversely, when discontinuing corticosteroid therapy, tacrolimus concentrations may increase. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: Corticosteroids (Systemic) may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids (Systemic).  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tisagenlecleucel: Corticosteroids (Systemic) may diminish the therapeutic effect of Tisagenlecleucel.  Management: Avoid use of corticosteroids as premedication or at any time during treatment with tisagenlecleucel, except in the case of life-threatening emergency (such as resistant cytokine release syndrome).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urea Cycle Disorder Agents: Corticosteroids (Systemic) may diminish the therapeutic effect of Urea Cycle Disorder Agents. More specifically, Corticosteroids (Systemic) may increase protein catabolism and plasma ammonia concentrations, thereby increasing the doses of Urea Cycle Disorder Agents needed to maintain these concentrations in the target range. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Vaccines (Live). Corticosteroids (Systemic) may diminish the therapeutic effect of Vaccines (Live).  Management: Doses equivalent to less than 2 mg/kg or 20 mg per day of prednisone administered for less than 2 weeks are not considered sufficiently immunosuppressive to create vaccine safety concerns. Higher doses and longer durations should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Warfarin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Warfarin. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780859\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780860\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed with corticosteroids in animal reproduction studies. Betamethasone crosses the placenta (Brownfoot 2013); and is partially metabolized by placental enzymes to an inactive metabolite (Murphy 2007). Some studies have shown an association between first trimester systemic corticosteroid use and oral clefts (Park-Wyllie 2000; Pradat 2003). Systemic corticosteroids may have an effect on fetal growth (decreased birth weight); however, information is conflicting (Lunghi 2010). Hypoadrenalism may occur in newborns following maternal use of corticosteroids during pregnancy; monitor.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Because antenatal corticosteroid administration may reduce the incidence of intraventricular hemorrhage, necrotizing enterocolitis, neonatal mortality, and respiratory distress syndrome, the injection is often used for antenatal fetal lung maturation in patients with preterm premature rupture of membranes or preterm labor who are at risk of preterm delivery. A single course of betamethasone is recommended for women between 24 and 34 weeks gestation who are at risk of delivering within 7 days, including those with ruptured membranes or multiple gestations. A single course of betamethasone may be considered for women beginning at 23 weeks gestation, who are at risk of delivering within 7 days, in consultation with the family. In addition, a single course of betamethasone may be given to women between 34 0/7 weeks and 36 6/7 weeks who are at risk of preterm delivery within 7 days and who have not previously received corticosteroids; use of concomitant tocolytics is not currently recommended and administration of late preterm corticosteroids has not been evaluated in women with intrauterine infection, multiple gestations, pregestational diabetes, or women who delivered previously by cesarean section at term. Multiple repeat courses are not recommended. However, in women with pregnancies less than 34 weeks gestation at risk for delivery within 7 days and who had a course of antenatal corticosteroids &gt;14 days prior, a single repeat course may be considered; use of a repeat course in women with premature rupture of membranes is controversial (ACOG 171 2016; ACOG 172 2016; ACOG 677 2016).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">When systemic corticosteroids are needed in pregnancy, it is generally recommended to use the lowest effective dose for the shortest duration of time, avoiding high doses during the first trimester (Leachman 2006; Lunghi 2010; Makol 2011; &Oslash;stensen 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24168317\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Intraocular pressure (if therapy &gt;6 weeks); weight, height, and linear growth (with chronic use); assess HPA suppression. Monitor blood pressure, serum glucose, potassium, calcium, hemoglobin, occult blood loss, and clinical presence of adverse effects. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780870\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Controls the rate of protein synthesis; depresses the migration of polymorphonuclear leukocytes, fibroblasts; reverses capillary permeability and lysosomal stabilization at the cellular level to prevent or control inflammation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49638561\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 64% (Peterson 1983)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic (Peterson 1983)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 6.5 hours (Peterson 1983)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: IV: 10 to 36 minutes (Peterson 1983)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (&lt;5% as unchanged drug) (Peterson 1983)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780906\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (ReadySharp Betamethasone Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg/5 mL (1): $573.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Betamethasone Sod Phos &amp; Acet Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 (3-3) mg/mL (5 mL): $61.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Celestone Soluspan Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 (3-3) mg/mL (5 mL): $44.88</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24799663\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Bei Shi Li (CN);</li>\n      <li>Betacort (SA);</li>\n      <li>Betagen (BD);</li>\n      <li>Betanoid (ZA);</li>\n      <li>Betasone (AE, QA, SA);</li>\n      <li>Betnelan (BD, IN, LK, PK);</li>\n      <li>Betnesol (BD, BE, CH, FR, IE, IL, IN, LB, PK);</li>\n      <li>Bufencon (MY);</li>\n      <li>Celestan Depot (DE);</li>\n      <li>Celestene Chronodose (FR);</li>\n      <li>Celeston (SE);</li>\n      <li>Celeston Chronodose (FI, NO, TR);</li>\n      <li>Celestone (AE, AR, BE, BH, CO, DE, EG, JO, KR, LB, LU, MX, PE, PL, PT, QA, SA, UY);</li>\n      <li>Celestone Chronodose (AE, AU, CH, ES, GR, IL, JO, LB, NZ);</li>\n      <li>Celestone Cronodose (PE, PY, UY);</li>\n      <li>Celestone Soluspan (MX);</li>\n      <li>Cidoten (CL);</li>\n      <li>Corteroid (AR);</li>\n      <li>Cortixyl Depot (PE);</li>\n      <li>Dacam RL (CL);</li>\n      <li>Diprofos Depot (DK, PT);</li>\n      <li>Diprophos (BG, CH, HU, SK);</li>\n      <li>Diprosone Depot (DE);</li>\n      <li>Diprospan (CN, DK, HK, IS, SG, TH, VN);</li>\n      <li>Flosetron (BG);</li>\n      <li>Inflacor (CO);</li>\n      <li>Lenasone (ZA);</li>\n      <li>Metamar (AR);</li>\n      <li>Solu Celestan (AT, DE);</li>\n      <li>Vistamethasone (TR);</li>\n      <li>Walacort (IN);</li>\n      <li>X-Beta (TZ)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG practice bulletins no. 139: premature rupture of membranes. <i>Obstet Gynecol</i>. 2013;122(4):918-930. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-systemic-pediatric-drug-information/abstract-text/24084566/pubmed\" target=\"_blank\" id=\"24084566\">24084566</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Betamethasone sodium phosphate and betamethasone acetate injectable suspension [prescribing information]. Shirley, NY: American Regent, Inc; December 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boot AM, Nauta J, Hokken-Koelega AC, Pols HA, de Ridder MA, de Muinck Keizer-Schrama SM. Renal transplantation and osteoporosis. <i>Arch Dis Child</i>. 1995;72(6):502-506. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-systemic-pediatric-drug-information/abstract-text/7618934/pubmed\" target=\"_blank\" id=\"7618934\">7618934</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bowman H, Lennard TW. Immunosuppressive drugs. <i>Br J Hosp Med</i>. 1992;48(9):570-573. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-systemic-pediatric-drug-information/abstract-text/1282440/pubmed\" target=\"_blank\" id=\"1282440\">1282440</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brownfoot FC, Gagliardi DI, Bain E, Middleton P, Crowther CA. Different corticosteroids and regimens for accelerating fetal lung maturation for women at risk of preterm birth. <i>Cochrane Database Syst Rev</i>. 2013;29;8:CD006764.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-systemic-pediatric-drug-information/abstract-text/23990333/pubmed\" target=\"_blank\" id=\"23990333\">23990333</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Buckmiller LM, Francis CL, Glade RS. Intralesional steroid injection for proliferative parotid hemangiomas. <i>Int J Pediatr Otorhinolaryngo</i>. 2008,72:81-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-systemic-pediatric-drug-information/abstract-text/18054392/pubmed\" target=\"_blank\" id=\"18054392\">18054392</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Celestone soluspan (betamethasone sodium phosphate and betamethasone acetate injectable suspension) [prescribing information]. Whitehouse Station, NY: Merck &amp; Co, Inc; May 2012. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chowdri NA, Darzi MA, Fazili Z, Iqbal S. Intralesional corticosteroid therapy for childhood cutaneous hemangiomas. <i>Ann Plast Surg</i>. 1994;33(1):46-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-systemic-pediatric-drug-information/abstract-text/7944196/pubmed\" target=\"_blank\" id=\"7944196\">7944196</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. <i>N Engl J Med</i>. 2003;348(8):727-734. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-systemic-pediatric-drug-information/abstract-text/12594318/pubmed\" target=\"_blank\" id=\"12594318\">12594318</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coursin DB, Wood KE. Corticosteroid supplementation for adrenal onsufficiency. <i>JAMA</i>. 2002;287(2):236-240. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-systemic-pediatric-drug-information/abstract-text/11779267/pubmed\" target=\"_blank\" id=\"11779267\">11779267</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gamsu HR, Mullinger BM, Donnai P, Dash CH. Antenatal administration of betamethasone to prevent respiratory distress syndrome in preterm infants: report of a UK Multicentre Trial. <i>Br J Obstet Gynaecol</i>. 1989;96(4):401-410. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-systemic-pediatric-drug-information/abstract-text/2665800/pubmed\" target=\"_blank\" id=\"2665800\">2665800</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goedert JJ, Vitale F, Lauria C, et al. Risk factors for classical Kaposi's Sarcoma. <i>J Natl Cancer Inst</i>. 2002;94(22):1712-1718.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-systemic-pediatric-drug-information/abstract-text/12441327/pubmed\" target=\"_blank\" id=\"12441327\">12441327</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goyal R, Watts P, Lane CM, Beck L, Gregory JW. Adrenal suppression and failure to thrive after steroid injections for periocular hemangioma. <i>Ophthalmology</i>. 2004;111(2):389-395.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-systemic-pediatric-drug-information/abstract-text/15019396/pubmed\" target=\"_blank\" id=\"15019396\">15019396</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grotz WH, Mundinger FA, Gugel B, Exner VM, Kirste G, Schollmeyer PJ. Bone mineral density after kidney transplantation: a cross-sectional study in 190-graft recipients up to 20 years after transplantation. <i>Transplantation</i>. 1995;59(7):982-986. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-systemic-pediatric-drug-information/abstract-text/7709459/pubmed\" target=\"_blank\" id=\"7709459\">7709459</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gutin PH. Corticosteroid therapy in patients with brain tumors. <i>Natl Cancer Inst Monogr</i>. 1977;46:151-156. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-systemic-pediatric-drug-information/abstract-text/349394/pubmed\" target=\"_blank\" id=\"349394\">349394</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Henderson JJ, Hartmann PE, Newnham JP, Simmer K. Effect of preterm birth and antenatal corticosteroid treatment on lactogenesis II in women. <i>Pediatrics</i>. 2008;121(1):e92-100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-systemic-pediatric-drug-information/abstract-text/18166549/pubmed\" target=\"_blank\" id=\"18166549\">18166549</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. <i>Arthritis Care Res (Hoboken)</i>. 2012;64(4):465-474.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-systemic-pediatric-drug-information/abstract-text/22563589/pubmed\" target=\"_blank\" id=\"22563589\">22563589</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kimberly RP. Glucocorticoids. <i>Curr Opin Rheumatol</i>. 1994;6(3):273-280. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-systemic-pediatric-drug-information/abstract-text/8060761/pubmed\" target=\"_blank\" id=\"8060761\">8060761</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koutroulis I, Papoutsis J, Kroumpouzos G. Atopic dermatitis in pregnancy: current status and challenges. <i>Obstet Gynecol Surv</i>. 2011;66(10):654-663.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-systemic-pediatric-drug-information/abstract-text/22112526/pubmed\" target=\"_blank\" id=\"22112526\">22112526</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kushner BJ. The treatment of periorbital infantile hemangioma with intralesional corticosteroid. <i>Plast Reconstruc Surg</i>. 1985;76(4):517-524.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-systemic-pediatric-drug-information/abstract-text/4034770/pubmed\" target=\"_blank\" id=\"4034770\">4034770</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lam DS, Fan DS, Ng JS, Yu CB, Wong CY, Cheung AY. Ocular hypertensive and anti-inflammatory responses to different dosages of topical dexamethasone in children: a randomized trial. <i>Clin Experiment Ophthalmol</i>. 2005;33(3):252-258.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-systemic-pediatric-drug-information/abstract-text/15932528/pubmed\" target=\"_blank\" id=\"15932528\">15932528</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leachman SA, Reed BR. The use of dermatologic drugs in pregnancy and lactation. <i>Dermatol Clin</i>. 2006;24(2):167-197.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-systemic-pediatric-drug-information/abstract-text/16677965/pubmed\" target=\"_blank\" id=\"16677965\">16677965</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leonard MB. Glucocorticoid-induced osteoporosis in children: impact of the underlying disease. <i>Pediatrics</i>. 2007;119 (Suppl 2):S166-174. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-systemic-pediatric-drug-information/abstract-text/17332238/pubmed\" target=\"_blank\" id=\"17332238\">17332238</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment of respiratory distress syndrome in premature infants. <i>Pediatrics</i>. 1972;50(4):515-525. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-systemic-pediatric-drug-information/abstract-text/4561295/pubmed\" target=\"_blank\" id=\"4561295\">4561295</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lowenthal RM, Jestrimski KW. Corticosteroid drugs: their role in oncological practice. <i>Med J Aust</i>. 1986;144(2):81-85. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-systemic-pediatric-drug-information/abstract-text/2417096/pubmed\" target=\"_blank\" id=\"2417096\">2417096</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lunghi L, Pavan B, Biondi C, et al. Use of glucocorticoids in pregnancy. <i>Curr Pharm Des</i>. 2010;16(32):3616-3637.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-systemic-pediatric-drug-information/abstract-text/20977425/pubmed\" target=\"_blank\" id=\"20977425\">20977425</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Makol A, Wright K, Amin S. Rheumatoid arthritis and pregnancy: safety considerations in pharmacological management. <i>Drugs</i>. 2011;71(15):1973-1987.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-systemic-pediatric-drug-information/abstract-text/21985166/pubmed\" target=\"_blank\" id=\"21985166\">21985166</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McGee S, Hirschmann J. Use of corticosteroids in treating infectious diseases. <i>Arch Intern Med</i>. 2008;168(10):1034-1046.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-systemic-pediatric-drug-information/abstract-text/18504331/pubmed\" target=\"_blank\" id=\"18504331\">18504331</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murphy VE, Fittock RJ, Zarzycki PK, Delahunty MM, Smith R, Clifton VL. Metabolism of synthetic steroids by the human placenta. <i>Placenta</i>. 2007;28(1):39-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-systemic-pediatric-drug-information/abstract-text/16549198/pubmed\" target=\"_blank\" id=\"16549198\">16549198</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &Oslash;stensen M, Forger F. Management of RA medications in pregnant patients. <i>Nat Rev Rheumatol</i>. 2009;5(7):382-390.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-systemic-pediatric-drug-information/abstract-text/19506586/pubmed\" target=\"_blank\" id=\"19506586\">19506586</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ost L, Wettrell G, Bj&ouml;rkhem I, Rane A, Prednisolone excretion in human milk. <i>J Pediatr</i>. 1985;106(6):1008-1011.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-systemic-pediatric-drug-information/abstract-text/3998938/pubmed\" target=\"_blank\" id=\"3998938\">3998938</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. <i>Teratology</i>. 2000;62(6):385-392.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-systemic-pediatric-drug-information/abstract-text/11091360/pubmed\" target=\"_blank\" id=\"11091360\">11091360</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pradat P, Robert-Gnansia E, Di Tanna GL, et al. First trimester exposure to corticosteroids and oral clefts. <i>Birth Defects Res A Clin Mol Teratol</i>. 2003;67(12):968-970.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-systemic-pediatric-drug-information/abstract-text/14745915/pubmed\" target=\"_blank\" id=\"14745915\">14745915</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prasetyono TO, Djoenaedi I. Efficacy of intralesional steroid injection in head and neck hemangioma: a systematic review.<i> Ann Plast Surg</i>. 2011;66(1):98-106.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-systemic-pediatric-drug-information/abstract-text/21042190/pubmed\" target=\"_blank\" id=\"21042190\">21042190</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Report of a Workshop by the British Association for Paediatric Nephrology and Research Unit, Royal College of Physicians. Consensus statement on management and audit potential for steroid responsive nephrotic syndrome, <i>Arch Dis Child</i>. 1994;70(2):151-157. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-systemic-pediatric-drug-information/abstract-text/8129444/pubmed\" target=\"_blank\" id=\"8129444\">8129444</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 95148 Version 90.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F23780847\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F23780848\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F24168309\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F24168315\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F23780904\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F23780850\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F24168316\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F24171540\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F24168310\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F23780920\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F23780863\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F23780864\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25820007\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F23780922\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F23780921\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F23780859\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F23780860\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F24168317\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F23780870\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F49638561\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F23780906\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F24799663\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/95148|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=betamethasone-systemic-drug-information\" class=\"drug drug_general\">Betamethasone (systemic): Drug information</a></li><li><a href=\"topic.htm?path=betamethasone-systemic-patient-drug-information\" class=\"drug drug_patient\">Betamethasone (systemic): Patient drug information</a></li></ul></div></div>","javascript":null}